A trial in chronic cough due to idiopathic pulmonary fibrosis (IPF)
What is the CANAL study?
The CANAL Study will involve around 60 participants in up to 15 study centres.
The CANAL Study is evaluating the safety and tolerability (how you feel when you take something), and effect on cough frequency (how often you cough), of an investigational study drug compared with placebo; a placebo looks exactly like the investigational study but contains no active medicine.
As this study is a crossover study, this means you will receive both the investigational study drug and the placebo at different times over the course of the study duration.
Is the study right for me?
Key Inclusion Criteria
- Diagnosed with Idiopathic Pulmonary Fibrosis
- Chronic cough > 8 weeks
- Moderate to severe daytime cough severity
Key Exclusion Criteria
- Interstitial lung disease (ILD) known to be caused by:
- Domestic and occupational environmental exposures
- Connective tissue disease
- Drug related toxicity
- Patients currently on continuous oxygen therapy for more than 16 hours a day
How long is the study?
The study will last about 14 weeks. There will be around 6 planned visits to the study centre and 4 visits that will be conducted over the telephone.
The investigational study drug is a tablet, which you will need to take 2 times a day. You will also be asked to wear a portable cough monitor at various times throughout the study.
Travel Assistance Policy: Study site staff will discuss travel assistance.
Study Sites Near You
Click on a marker to find a study site near you.
- Green Marker: Recruiting
- Yellow Marker: Not yet recruiting, expected to start recruiting in 2021
If you are not located near a study site but are willing to travel, study site staff will discuss travel assistance.
Connect Me To a Study Site
Click the ‘CONNECT’ button to send an email to our team to learn more about the CANAL Study.
A member of our team will get back to you within 48-72 hours.